96 related articles for article (PubMed ID: 20853351)
1. Extended follow-up safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: two-year follow-up from the E-Five Registry.
Meredith I; Rothman M; Erglis A; Parikh K; Lotan C;
Catheter Cardiovasc Interv; 2011 Jun; 77(7):993-1000. PubMed ID: 20853351
[TBL] [Abstract][Full Text] [Related]
2. Safety and effectiveness of the Endeavor zotarolimus-eluting stent in real-world clinical practice: 12-month data from the E-Five registry.
Lotan C; Meredith IT; Mauri L; Liu M; Rothman MT;
JACC Cardiovasc Interv; 2009 Dec; 2(12):1227-35. PubMed ID: 20129549
[TBL] [Abstract][Full Text] [Related]
3. Four-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial.
Garg S; Serruys PW; Miquel-Hebert K;
Catheter Cardiovasc Interv; 2011 Jun; 77(7):1012-7. PubMed ID: 20824770
[TBL] [Abstract][Full Text] [Related]
4. Resolute Italian study in all comers: immediate and one-year outcomes.
Romagnoli E; Godino C; Ielasi A; Gasparini G; Tzifos V; Sciahbasi A; Lioy E; Presbitero P; Colombo A; Sangiorgi G
Catheter Cardiovasc Interv; 2012 Mar; 79(4):567-74. PubMed ID: 21805557
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel and sirolimus eluting stents versus bare metal stents: long-term risk of stent thrombosis and other outcomes. From the Western Denmark Heart Registry.
Jensen LO; Tilsted HH; Thayssen P; Kaltoft A; Maeng M; Lassen JF; Hansen KN; Madsen M; Ravkilde J; Johnsen SP; Sørensen HT; Thuesen L
EuroIntervention; 2010 Apr; 5(8):898-905. PubMed ID: 20542774
[TBL] [Abstract][Full Text] [Related]
6. Four-year clinical outcome of sirolimus- and paclitaxel-eluting stents compared to bare-metal stents for the percutaneous treatment of stable coronary artery disease.
Simsek C; Onuma Y; Magro M; de Boer S; Battes L; van Domburg RT; Boersma E; Serruys PW;
Catheter Cardiovasc Interv; 2010 Jul; 76(1):41-9. PubMed ID: 20310019
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
[TBL] [Abstract][Full Text] [Related]
8. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
[TBL] [Abstract][Full Text] [Related]
9. Usage patterns and 1-year outcomes with the TAXUS Liberté stent: results of the TAXUS OLYMPIA registry.
Ahmed WH; Mendiz OA; Thomas MR;
Catheter Cardiovasc Interv; 2011 Jun; 77(7):979-92. PubMed ID: 20853350
[TBL] [Abstract][Full Text] [Related]
10. Outcomes in patients with renal impairment undergoing percutaneous coronary intervention and implantation of the Endeavor zotarolimus-eluting stent: 1- and 2-year data from the E-Five Registry.
Rothman MT; Jain AK;
Catheter Cardiovasc Interv; 2012 Nov; 80(6):885-92. PubMed ID: 22517785
[TBL] [Abstract][Full Text] [Related]
11. Real-world safety and efficacy of the endeavor zotarolimus-eluting stent: early data from the E-Five Registry.
Jain AK; Meredith IT; Lotan C; Rothman MT; Pateraki S;
Am J Cardiol; 2007 Oct; 100(8B):77M-83M. PubMed ID: 17950836
[TBL] [Abstract][Full Text] [Related]
12. Spatial distribution of neo-intimal hyperplasia 6 months after zotarolimus-eluting stent implantation, analysed by optical coherence tomography.
Souteyrand G; Levesque S; Ouchchane L; Sarry L; Eschalier R; Lusson JR; Motreff P
Arch Cardiovasc Dis; 2011 Mar; 104(3):147-54. PubMed ID: 21497303
[TBL] [Abstract][Full Text] [Related]
13. Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study.
Fajadet J; Wijns W; Laarman GJ; Kuck KH; Ormiston J; Baldus S; Hauptmann KE; Suttorp MJ; Drzewiecki J; Pieper M; Schultheiss HP; Mauri L
EuroIntervention; 2010 Nov; 6(5):562-7. PubMed ID: 21044908
[TBL] [Abstract][Full Text] [Related]
14. Another small step for small vessels.
Morrison DA
Catheter Cardiovasc Interv; 2010 Jul; 76(1):67-9. PubMed ID: 20578195
[No Abstract] [Full Text] [Related]
15. One-year outcomes of patients with the zotarolimus-eluting coronary stent: RESOLUTE International Registry.
Neumann FJ; Widimsky P; Belardi JA
EuroIntervention; 2012 Feb; 7(10):1181-8. PubMed ID: 22334317
[TBL] [Abstract][Full Text] [Related]
16. Angiographic and intravascular ultrasound findings following implantation of the Endeavor zotarolimus-eluting stents in patients from the real-world clinical practice.
Feres F; Andrade PB; Costa RA; de Ribamar Costa J; Abizaid A; Staico R; Tanajura LF; Siqueira D; Maia JP; Lasave L; Sousa AG; Sousa JE
EuroIntervention; 2009 Aug; 5(3):355-62. PubMed ID: 19736161
[TBL] [Abstract][Full Text] [Related]
17. Outcomes after differential use of drug-eluting stents in diabetic patients: 1-year results from the DES.DE (Drug-Eluting Stent.DEutschland) registry.
Akin I; Bufe A; Eckardt L; Reinecke H; Richardt G; Kuck KH; Senges J; Schneider S; Nienaber CA;
Catheter Cardiovasc Interv; 2010 Jul; 76(1):50-7. PubMed ID: 20578192
[TBL] [Abstract][Full Text] [Related]
18. More openness and a little less strut: two good ideas for stents and the people who implant them.
Morrison DA
Catheter Cardiovasc Interv; 2010 Nov; 76(5):652-3. PubMed ID: 20976746
[No Abstract] [Full Text] [Related]
19. Sirolimus- versus paclitaxel-eluting stents for unselected patients with coronary artery disease.
Park SJ
Catheter Cardiovasc Interv; 2011 Jan; 77(1):13-4. PubMed ID: 21181967
[No Abstract] [Full Text] [Related]
20. Nevo stent: a successful stent makeover.
Belardi JA
Catheter Cardiovasc Interv; 2011 Jan; 77(1):52-3. PubMed ID: 21181969
[No Abstract] [Full Text] [Related]
[Next] [New Search]
